RPL14A Antibody

What are the validated applications for RPL14 antibodies?

RPL14 antibodies have been validated for multiple experimental applications, with performance varying by manufacturer and clone. Based on comprehensive validation studies, the following applications have been confirmed:

For optimal results, it is recommended to titrate the antibody concentration for each specific experimental system . When selecting between applications, consider that WB typically offers higher sensitivity for protein detection, while IHC/IF provides valuable information about subcellular localization .

What is the molecular weight range for detecting RPL14 protein?

When working with RPL14 antibodies, researchers should be aware of potential discrepancies between calculated and observed molecular weights:

• Calculated molecular weight: 23 kDa

• Observed molecular weight range: 25-30 kDa

This discrepancy is commonly observed and may be attributed to post-translational modifications, particularly phosphorylation, acetylation, ubiquitination, and methylation that affect protein migration in SDS-PAGE . When validating a new RPL14 antibody, confirmation of the appropriate molecular weight band is critical before proceeding with experimental applications .

How should RPL14 antibodies be stored to maintain optimal activity?

Proper storage is critical for maintaining antibody performance across experimental replicates. For RPL14 antibodies:

For best practices, create single-use aliquots upon receiving the antibody to minimize freeze-thaw cycles, as repeated freezing and thawing can significantly reduce antibody activity . Some formulations contain BSA as a stabilizer, though BSA-free options are available for applications where BSA might interfere .

What controls should be included when validating RPL14 antibody specificity?

Proper validation of RPL14 antibody specificity requires multiple control strategies:

• Positive controls: Include cell lines with confirmed RPL14 expression (HEK-293, HepG2, HeLa, MCF-7)

• Enhanced validation approaches:

  • siRNA knockdown: Evaluate decrease in antibody staining intensity after RPL14 downregulation

  • GFP-tagged validation: Assess signal overlap between antibody staining and GFP-tagged RPL14 protein

  • Independent antibodies: Compare staining patterns using antibodies targeting different epitopes of RPL14

• Tissue controls: Include tissues with known RPL14 expression patterns (liver tissue shows reliable expression)

• Blocking peptide: Use the immunogenic peptide to compete for antibody binding in parallel experiments

How can RPL14 antibodies be optimized for immunohistochemistry in different tissue types?

Optimizing RPL14 antibodies for immunohistochemistry requires careful consideration of tissue-specific factors:

For human lymph node tissue, RPL14 antibody staining typically shows strong cytoplasmic positivity in reaction center cells and lymphoid cells outside the reaction center . When working with paraffin-embedded tissues, heat-induced epitope retrieval (HIER) at pH 6.0 is recommended, though optimization may be required for specific tissue types .

What approaches can be used to study RPL14 post-translational modifications using antibody-based methods?

RPL14 undergoes multiple post-translational modifications that can be studied using specialized antibody approaches:

When studying these modifications, it's often beneficial to combine immunoprecipitation with RPL14 antibodies followed by western blotting with modification-specific antibodies . This approach allows for enrichment of the target protein before assessing its modification state.

What are common sources of background in RPL14 antibody applications and how can they be mitigated?

Background issues with RPL14 antibodies can arise from several sources, with specific mitigation strategies:

For immunofluorescence applications, autofluorescence can be a significant issue, particularly in tissues with high lipofuscin content. This can be mitigated by using Sudan Black B treatment or commercially available autofluorescence quenchers after the secondary antibody incubation .

How should researchers interpret discrepancies between calculated and observed molecular weights for RPL14?

Interpreting molecular weight discrepancies for RPL14 requires understanding of several biological and technical factors:

• Post-translational modifications: RPL14 undergoes multiple modifications including phosphorylation (Y14, T43), acetylation (K23), ubiquitination (K23), and methylation (R46) that can alter its electrophoretic mobility

• Technical factors affecting migration:

  • SDS-PAGE percentage (higher percentage gels provide better resolution in the 20-30 kDa range)

  • Buffer systems (Tris-glycine vs. Tris-tricine)

  • Reduction conditions (complete vs. incomplete reduction)

• Validation approaches:

  • Compare migration with recombinant RPL14 protein

  • Pre-absorption with immunizing peptide to confirm specificity

  • Treat lysates with phosphatase to assess contribution of phosphorylation

The observed 25-30 kDa band for RPL14 (compared to calculated 23 kDa) is consistent across multiple antibody sources and likely represents the fully modified native protein .

How does RPL14 expression differ in cancer tissues compared to normal tissues?

Research has identified significant alterations in RPL14 expression in certain cancer types:

In nasopharyngeal carcinoma specifically, studies have demonstrated that RPL14 overexpression inhibits cancer cell proliferation, invasion, and migration, suggesting its potential role as an antioncogene . The protein expression shows a significant correlation with NPC T classification and N classification, indicating potential prognostic value .

What is the functional significance of RPL14 in cancer progression?

Functional studies have revealed important roles for RPL14 in cancer biology:

• Cell proliferation: RPL14 overexpression significantly inhibits NPC cell proliferation as demonstrated by CCK-8 assay and colony formation assays

• Cell cycle regulation: RPL14 overexpression blocks NPC cells in S phase of the cell cycle

• Metastatic potential: RPL14 suppresses cell migration and invasion in NPC models as shown by transwell and scratch healing assays

• Epithelial-mesenchymal transition: RPL14 expression correlates closely with EMT biomarkers including E-cadherin, N-cadherin, and vimentin

These findings suggest that RPL14 functions as an antioncogene in certain cancer types, with potential as a therapeutic target or prognostic marker. When investigating these functions, researchers should employ validated RPL14 antibodies in combination with functional assays to determine the impact of RPL14 expression modulation .

What are the best practices for using RPL14 antibodies in autoimmune disease research?

When studying RPL14 autoantibodies in autoimmune conditions such as systemic lupus erythematosus (SLE), several methodological considerations are critical:

• Antigen preparation: Use purified recombinant RPL14 protein or GST-L14 fusion protein as the target antigen for detection of autoantibodies

• Detection methods:

  • Immunoblotting provides high specificity but moderate sensitivity

  • ELISA offers higher throughput capabilities for screening larger patient cohorts

  • Immunoprecipitation can detect conformational epitopes potentially missed by other methods

• Control selection: Include healthy controls and disease controls (e.g., other autoimmune conditions like dermatomyositis, polymyositis, systemic sclerosis)

• Quantification: Consider both prevalence (percentage of positive patients) and titer (strength of reactivity) in analyses

In SLE research specifically, antibody activity against GST-L14 was detected in 7 out of 126 SLE patients but not in any control subjects, suggesting that while not highly prevalent, anti-RPL14 antibodies may have utility as part of a broader panel of autoantibody biomarkers .

How can advanced multiplexing techniques be applied with RPL14 antibodies?

Emerging multiplexing approaches offer powerful ways to study RPL14 in complex biological contexts:

• Multiplexed immunofluorescence:

  • Combine RPL14 antibodies with markers of cell proliferation, cell cycle, or EMT

  • Requires careful selection of compatible primary antibodies from different host species

  • Sequential staining protocols may be necessary to avoid cross-reactivity

• Mass cytometry (CyTOF) applications:

  • Metal-conjugated RPL14 antibodies enable high-dimensional analysis

  • Allows simultaneous detection of 40+ proteins without spectral overlap concerns

  • Particularly valuable for studying RPL14 in heterogeneous tissues

• Spatial transcriptomics integration:

  • Correlate RPL14 protein expression with spatial gene expression data

  • Provides insights into regulatory mechanisms in tissue context